hERG-related drug toxicity and models for predicting hERG liability and QT prolongation

Bibliography

• De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1-18
   PubMed Web of Science ®Google Scholar
• Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891-9
   PubMed Web of Science ®Google Scholar
• De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes: an overview. Drug Saf 2002;25:263-86
   PubMed Web of Science ®Google Scholar
• Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.Eur Heart J 2000;21:1216-31
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-9
   PubMed Web of Science ®Google Scholar
• Recanatini M, Poluzzi E, Masetti M, et al. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005;25:133-66
   PubMed Web of Science ®Google Scholar
• Raschi E, Vasina V, Poluzzi E, De Ponti F. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res 2008;57:181-95
   PubMed Web of Science ®Google Scholar
• Dumotier BM, Deurinck M, Yang Y, et al. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis. Pharmacol Ther 2008;119:152-9
   PubMed Web of Science ®Google Scholar
• Witchel HJ. The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets 2007;11:321-36
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals; availability. Notice. Fed Regist 2005;70:61133-4
   PubMedGoogle Scholar
• International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist 2005;70:61134-5
   PubMedGoogle Scholar
• Zitron E, Scholz E, Owen RW, et al. QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 2005;111:835-8
   PubMed Web of Science ®Google Scholar
• Scholz EP, Zitron E, Kiesecker C, et al. Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656. Nutr Metab Cardiovasc Dis 2007;17:666-75
   PubMed Web of Science ®Google Scholar
• Kelemen K, Kiesecker C, Zitron E, et al. Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels. Biochem Biophys Res Commun 2007;364:429-35
   PubMed Web of Science ®Google Scholar
• Lin C, Ke X, Ranade V, Somberg J. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology 2008;110:145-52
   PubMed Web of Science ®Google Scholar
• Guizy M, Arias C, David M, et al. {Omega}-3 and {omega}-6 polyunsaturated fatty acids block HERG channels. Am J Physiol Cell Physiol 2005;289:C1251-60
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu XS, Diochot S, et al. APETx1 from sea anemone Anthopleura elegantissima is a gating modifier peptide toxin of the human ether-a-go-go-related potassium channel. Mol Pharmacol 2007;72:259-68
   PubMed Web of Science ®Google Scholar
• Hill AP, Campbell TJ, Bansal PS, et al. The S631A mutation causes a mechanistic switch in the block of hERG channels by CnErg1. Biophys J 2007;93:L32-4
   PubMed Web of Science ®Google Scholar
• Hill AP, Sunde M, Campbell TJ, Vandenberg JI. Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys J 2007;92:3915-29
   PubMed Web of Science ®Google Scholar
• Pardo-Lopez L, Zhang M, Liu J, et al. Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule. J Biol Chem 2002;277:16403-11
   PubMed Web of Science ®Google Scholar
• Wanke E, Restano-Cassulini R. Toxins interacting with ether-a-go-go-related gene voltage-dependent potassium channels. Toxicon 2007;49:239-48
   PubMed Web of Science ®Google Scholar
• Restano-Cassulini R, Korolkova YV, Diochot S, et al. Species diversity and peptide toxins blocking selectivity of ether-a-go-go-related gene subfamily K+ channels in the central nervous system. Mol Pharmacol 2006;69:1673-83
   PubMed Web of Science ®Google Scholar
• Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999;10:272-82
   PubMed Web of Science ®Google Scholar
• Vandenberg JI, Walker BD, Campbell TJ. HERG K+ channels: friend and foe. Trends Pharmacol Sci 2001;22:240-6
   PubMed Web of Science ®Google Scholar
• Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52:557-94
   PubMed Web of Science ®Google Scholar
• Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001;110:385-98
   PubMed Web of Science ®Google Scholar
• Tseng GN. I(Kr): the hERG channel. J Mol Cell Cardiol 2001;33:835-49
   PubMed Web of Science ®Google Scholar
• Roden DM, George AL Jr. Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997;273:H511-25
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Gomez R, et al. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004;62:9-33
   PubMed Web of Science ®Google Scholar
• Shibata EF, Drury T, Refsum H, et al. Contributions of a transient outward current to repolarization in human atrium. Am J Physiol 1989;257:H1773-81
   PubMed Web of Science ®Google Scholar
• Mubagwa K, Flameng W, Carmeliet E. Resting and action potentials of nonischemic and chronically ischemic human ventricular muscle. J Cardiovasc Electrophysiol 1994;5:659-71
   PubMed Web of Science ®Google Scholar
• Oudit GY, Kassiri Z, Sah R, et al. The molecular physiology of the cardiac transient outward potassium current (I(to)) in normal and diseased myocardium. J Mol Cell Cardiol 2001;33:851-72
   PubMed Web of Science ®Google Scholar
• Kennerdy A, Thomas P, Sheridan DJ. Generalized seizures as the presentation of flecainide toxicity. Eur Heart J 1989;10:950-4
   PubMed Web of Science ®Google Scholar
• Platia EV, Estes M, Heine DL, et al. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 1985;55:956-62
   PubMed Web of Science ®Google Scholar
• Bruelle P, LeFrant JY, de La Coussaye JE, et al. Comparative electrophysiologic and hemodynamic effects of several amide local anesthetic drugs in anesthetized dogs. Anesth Analg 1996;82:648-56
   PubMed Web of Science ®Google Scholar
• Lacerda AE, Kuryshev YA, Chen Y, et al. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther 2008;324:427-33
   PubMed Web of Science ®Google Scholar
• Siebrands CC, Schmitt N, Friederich P. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656. Anesthesiology 2005;103:102-12
   PubMed Web of Science ®Google Scholar
• Cordes JS, Sun Z, Lloyd DB, et al. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 2005;145:15-23
   PubMed Web of Science ®Google Scholar
• Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005;312:316-23
   PubMed Web of Science ®Google Scholar
• Katchman AN, Koerner J, Tosaka T, et al. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006;316:1098-106
   PubMed Web of Science ®Google Scholar
• Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2004;109:26-9
   PubMed Web of Science ®Google Scholar
• Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004;66:33-44
   PubMed Web of Science ®Google Scholar
• Wang L, Wible BA, Wan X, Ficker E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 2007;320:525-34
   PubMed Web of Science ®Google Scholar
• Hancox JC, Mitcheson JS. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br J Pharmacol 2006;149:457-9
   PubMed Web of Science ®Google Scholar
• Rajamani S, Eckhardt LL, Valdivia CR, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006;149:481-9
   PubMed Web of Science ®Google Scholar
• Guo J, Massaeli H, Li W, et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 2007;321:911-20
   PubMed Web of Science ®Google Scholar
• van der Heyden MA, Smits ME, Vos MA. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 2008;153:406-9
   PubMed Web of Science ®Google Scholar
• Takemasa H, Nagatomo T, Abe H, et al. Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol 2008;153:439-47
   PubMed Web of Science ®Google Scholar
• Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72
   PubMed Web of Science ®Google Scholar
• Roden DM. Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21:1029-34
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Heterogeneity and cardiac arrhythmias: an overview. Heart Rhythm 2007;4:964-72
   PubMed Web of Science ®Google Scholar
• Lu HR, Vlaminckx E, Van de Water A, Gallacher DJ. Calmodulin antagonist W-7 prevents sparfloxacin-induced early afterdepolarizations (EADs) in isolated rabbit purkinje fibers: importance of beat-to-beat instability of the repolarization. J Cardiovasc Electrophysiol 2006;17:415-22
   PubMed Web of Science ®Google Scholar
• Hamlin RL, Kijtawornrat A. Use of the rabbit with a failing heart to test for torsadogenicity. Pharmacol Ther 2008;119:179-85
   PubMed Web of Science ®Google Scholar
• Finlayson K, Witchel HJ, McCulloch J, Sharkey J. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 2004;500:129-42
   PubMed Web of Science ®Google Scholar
• Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004;15:475-95
   PubMed Web of Science ®Google Scholar
• Lawrence CL, Pollard CE, Hammond TG, Valentin JP. Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods 2005;52:46-59
   PubMedGoogle Scholar
• Bass AS, Tomaselli G, Bullingham R 3rd, Kinter LB. Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 2005;52:12-21
   PubMedGoogle Scholar
• Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 2006;259:70-80
   PubMed Web of Science ®Google Scholar
• Thomsen MB, Matz J, Volders PG, Vos MA. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 2006;112:150-70
   PubMed Web of Science ®Google Scholar
• Lawrence CL, Pollard CE, Hammond TG, Valentin JP. In vitro models of proarrhythmia. Br J Pharmacol 2008;154:1516-22
   PubMed Web of Science ®Google Scholar
• Gintant GA. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 2008;119:199-209
   PubMed Web of Science ®Google Scholar
• Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008;119:118-32
   PubMed Web of Science ®Google Scholar
• Carlsson L. Drug-induced torsade de pointes: the perspectives of industry. Eur Heart J Suppl 2001;3:K114-K120
   Web of Science ®Google Scholar
• Gintant GA, Limberis JT, McDermott JS, et al. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 2001;37:607-18
   PubMed Web of Science ®Google Scholar
• Hamlin RL, Cruze CA, Mittelstadt SW, et al. Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. J Pharmacol Toxicol Methods 2004;49:15-23
   PubMedGoogle Scholar
• Aubert M, Osterwalder R, Wagner B, et al. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans. Drug Saf 2006;29:237-54
   PubMed Web of Science ®Google Scholar
• Lu HR, Vlaminckx E, Van de Water A, et al. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2006;553:229-39
   PubMed Web of Science ®Google Scholar
• Cavero I, Yan GX, Lux R, Steinhoff U. Safety pharmacology and prolongation of the QT interval. J Electrocardiol 2007;40:S58-61
   Web of Science ®Google Scholar
• Cavero I, Crumb-Wj J. Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs. Eur Heart J Suppl 2001;3:K53-63
   Web of Science ®Google Scholar
• Lacerda AE, Kramer J, Shen KZ, et al. Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J Suppl 2001;3:K23-30
   Google Scholar
• Witchel HJ, Pabbathi VK, Hofmann G, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002;512:59-66
   PubMed Web of Science ®Google Scholar
• Fossa AA, Gorczyca W, Wisialowski T, et al. Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods 2007;55:78-85
   PubMedGoogle Scholar
• Martin RL, McDermott JS, Salmen HJ, et al. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 2004;43:369-79
   PubMed Web of Science ®Google Scholar
• Lu HR, Vlaminckx E, Gallacher DJ. Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation. J Pharmacol Toxicol Methods 2008;57:1-8
   PubMedGoogle Scholar
• Cavero I, Crumb W. The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance. April 11-12, 2005, Bethesda, MD, USA. Expert Opin Drug Saf 2005;4:795-9
   PubMedGoogle Scholar
• Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol 2009;29:183-206
   PubMed Web of Science ®Google Scholar
• Kirsch GE, Trepakova ES, Brimecombe JC, et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004;50:93-101
   PubMedGoogle Scholar
• Wible BA, Hawryluk P, Ficker E, et al. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005;52:136-45
   PubMedGoogle Scholar
• Bass AS, Darpo B, Breidenbach A, et al. International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol 2008;154:1491-501
   PubMed Web of Science ®Google Scholar
• Bass AS, Darpo B, Valentin JP, et al. Moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol 2008;154:1550-3
   PubMed Web of Science ®Google Scholar
• Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103:2004-13
   PubMed Web of Science ®Google Scholar
• Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005;2:758-72
   PubMed Web of Science ®Google Scholar
• Hondeghem LM. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 2006;17:337-40
   PubMed Web of Science ®Google Scholar
• Milberg P, Hilker E, Ramtin S, et al. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 2007;18:647-54
   PubMed Web of Science ®Google Scholar
• Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998;98:1928-36
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J Electrocardiol 2004;37(Suppl):15-24
   PubMed Web of Science ®Google Scholar
• Hondeghem LM, Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J CardiovascPharmacol 2003;41:14-24
   Web of Science ®Google Scholar
• Hondeghem LM, Lu HR, van Rossem K, De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 2003;14:287-94
   PubMed Web of Science ®Google Scholar
• Lawrence CL, Bridgland-Taylor MH, Pollard CE, et al. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol 2006;149:845-60
   PubMed Web of Science ®Google Scholar
• Chen X, Cordes JS, Bradley JA, et al. Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs. J Pharmacol Toxicol Methods 2006;54:261-72
   PubMedGoogle Scholar
• Steidl-Nichols JV, Hanton G, Leaney J, et al. Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model. J Pharmacol Toxicol Methods 2008;57:9-22
   PubMedGoogle Scholar
• Liu T, Brown BS, Wu Y, et al. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006;3:948-56
   PubMed Web of Science ®Google Scholar
• Pacher P, Ungvari Z, Nanasi PP, et al. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999;6:469-80
   PubMed Web of Science ®Google Scholar
• Nau C, Seaver M, Wang SY, Wang GK. Block of human heart hH1 sodium channels by amitriptyline. J Pharmacol Exp Ther 2000;292:1015-23
   PubMed Web of Science ®Google Scholar
• Isenberg G, Tamargo J. Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes. Eur J Pharmacol 1985;108:121-31
   PubMed Web of Science ®Google Scholar
• Delpon E, Tamargo J, Sanchez-Chapula J. Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 1991;344:645-52
   PubMed Web of Science ®Google Scholar
• Reich MR, Ohad DG, Overall KL, Dunham AE. Electrocardiographic assessment of antianxiety medication in dogs and correlation with serum drug concentration. J Am Vet Med Assoc 2000;216:1571-5
   PubMed Web of Science ®Google Scholar
• Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45
   PubMed Web of Science ®Google Scholar
• Titier K, Canal M, Deridet E, et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004;199:52-60
   PubMed Web of Science ®Google Scholar
• Pearlstein R, Vaz R, Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 2003;46:2017-22
   PubMed Web of Science ®Google Scholar
• Ekins S. In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem Soc Trans 2003;31:611-4
   PubMed Web of Science ®Google Scholar
• Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005;10:149-55
   PubMed Web of Science ®Google Scholar
• Recanatini M, Cavalli A, Masetti M. In silico modelling–pharmacophores and hERG channel models. Novartis Found Symp 2005;266:171-81; discussion 81-5
   PubMedGoogle Scholar
• Ermondi G, Visentin S, Caron G. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K(+) channel blockers. Eur J Med Chem 2009;44:1926-32
   PubMed Web of Science ®Google Scholar
• Recanatini M, Cavalli A, Masetti M. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations. ChemMedChem 2008;3:523-35
   PubMed Web of Science ®Google Scholar
• Thai KM, Ecker GF. Predictive models for HERG channel blockers: ligand-based and structure-based approaches. Curr Med Chem 2007;14:3003-26
   PubMed Web of Science ®Google Scholar
• Noble D. Computational models of the heart and their use in assessing the actions of drugs. J Pharmacol Sci 2008;107:107-17
   PubMed Web of Science ®Google Scholar
• Ekins S, Crumb WJ, Sarazan RD, et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002;301:427-34
   PubMed Web of Science ®Google Scholar
• Cavalli A, Poluzzi E, De Ponti F, Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem 2002;45:3844-53
   PubMed Web of Science ®Google Scholar
• Pearlstein RA, Vaz RJ, Kang J, et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 2003;13:1829-35
   PubMed Web of Science ®Google Scholar
• Recanatini M, Cavalli A. QSAR and pharmacophores for drugs involved in hERG blockage. In: Vaz R, Klabunde T, editors, Antitargets in drug discovery. Weinheim: WILEY-VCH Verlag GmbH 2008
   Google Scholar
• Leong MK. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability. Chem Res Toxicol 2007;20:217-26
   PubMed Web of Science ®Google Scholar
• Gavaghan CL, Arnby CH, Blomberg N, et al. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J Comput Aided Mol Des 2007;21:189-206
   PubMed Web of Science ®Google Scholar
• Diller DJ, Hobbs DW. Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation. J Comput Aided Mol Des 2007;21:379-93
   PubMed Web of Science ®Google Scholar
• Johnson SR, Yue H, Conder ML, et al. Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR. Bioorg Med Chem 2007;15:6182-92
   PubMed Web of Science ®Google Scholar
• Obrezanova O, Csanyi G, Gola JM, Segall MD. Gaussian processes: a method for automatic QSAR modeling of ADME properties. J Chem Inf Model 2007;47:1847-57
   PubMed Web of Science ®Google Scholar
• Garg D, Gandhi T, Gopi Mohan C. Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques. J Mol Graph Model 2008;26:966-76
   PubMed Web of Science ®Google Scholar
• Kramer C, Beck B, Kriegl JM, Clark T. A composite model for HERG blockade. ChemMedChem 2008;3:254-65
   PubMed Web of Science ®Google Scholar
• Mente S, Gallaschun R, Schmidt A, et al. Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities. Bioorg Med Chem Lett 2008;18:6088-92
   PubMed Web of Science ®Google Scholar
• Roche O, Trube G, Zuegge J, et al. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem 2002;3:455-9
   PubMed Web of Science ®Google Scholar
• Ivanciuc O. Applications of support vector machines in chemistry. In: Lipkowitz KB, Cundari TR, editors, Reviews in Computational Chemistry, Volume 23. Weinheim: Wiley-VCH; 2007. p. 291-400
   Google Scholar
• Nisius B, Göller AH. Similarity-based classifier using topomers to provide a knowledge base for hERG channel inhibition. J Chem Inf Model 2009;49:247-56
   PubMed Web of Science ®Google Scholar
• Thai KM, Ecker GF. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers. Mol Divers 2009; in press, doi 10.1007/s11030-009-9117-0
   PubMedGoogle Scholar
• Hanson LA, Bass AS, Gintant G, et al. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 2006;54:116-29
   PubMedGoogle Scholar
• Trepakova ES, Koerner J, Pettit SD, Valentin JP. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 2009; in press, doi: 10.1016/j.vascn.2009.05.002
   PubMedGoogle Scholar
• Holbrook M, Malik M, Shah RR, Valentin JP. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development? J Pharmacol Toxicol Methods 2009;59:21-8
   PubMedGoogle Scholar
• Aptula AO, Cronin MT. Prediction of hERG K+ blocking potency: application of structural knowledge. SAR QSAR Environ Res 2004;15:399-411
   PubMed Web of Science ®Google Scholar
• Yoshida K, Niwa T. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J Chem Inf Model 2006;46:1371-8
   PubMed Web of Science ®Google Scholar
• Seierstad M, Agrafiotis DK. A QSAR model of HERG binding using a large, diverse, and internally consistent training set. Chem Biol Drug Des 2006;67:284-96
   PubMed Web of Science ®Google Scholar
• Coi A, Massarelli I, Murgia L, et al. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg Med Chem 2006;14:3153-9
   PubMed Web of Science ®Google Scholar
• Song M, Clark M. Development and evaluation of an in silico model for hERG binding. J Chem Inf Model 2006;46:392-400
   PubMed Web of Science ®Google Scholar
• Keseru GM. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett 2003;13:2773-5
   PubMed Web of Science ®Google Scholar
• Aronov AM, Goldman BB. A model for identifying HERG K+ channel blockers. Bioorg Med Chem 2004;12:2307-15
   PubMed Web of Science ®Google Scholar
• Bains W, Basman A, White C. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog Biophys Mol Biol 2004;86:205-33
   PubMed Web of Science ®Google Scholar
• Yap CW, Cai CZ, Xue Y, Chen YZ. Prediction of torsade-causing potential of drugs by support vector machine approach. Toxicol Sci 2004;79:170-7
   PubMed Web of Science ®Google Scholar
• Tobita M, Nishikawa T, Nagashima R. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg Med Chem Lett 2005;15:2886-90
   PubMed Web of Science ®Google Scholar
• Dubus E, Ijjaali I, Petitet F, Michel A. In silico classification of HERG channel blockers: a knowledge-based strategy. ChemMedChem 2006;1:622-30
   PubMed Web of Science ®Google Scholar
• Sun H. An accurate and interpretable bayesian classification model for prediction of HERG liability. ChemMedChem 2006;1:315-22
   PubMed Web of Science ®Google Scholar
• Gepp MM, Hutter MC. Determination of hERG channel blockers using a decision tree. Bioorg Med Chem 2006;14:5325-32
   PubMed Web of Science ®Google Scholar
• Ekins S, Balakin KV, Savchuk N, Ivanenkov Y. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques. J Med Chem 2006;49:5059-71
   PubMed Web of Science ®Google Scholar
• Aronov AM. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. J Med Chem 2006;49:6917-21
   PubMed Web of Science ®Google Scholar
• Waring MJ, Johnstone C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg Med Chem Lett 2007;17:1759-64
   PubMed Web of Science ®Google Scholar
• Filz O, Lagunin A, Filimonov D, Poroikov V. Computer-aided prediction of QT-prolongation. SAR QSAR Environ Res 2008;19:81-90
   PubMed Web of Science ®Google Scholar
• Thai KM, Ecker GF. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem 2008;16:4107-19
   PubMed Web of Science ®Google Scholar
• Li Q, Jorgensen FS, Oprea T, et al. hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol Pharm 2008;5:117-27
   PubMed Web of Science ®Google Scholar
• Jia L, Sun H. Support vector machines classification of hERG liabilities based on atom types. Bioorg Med Chem 2008;16:6252-60
   PubMed Web of Science ®Google Scholar
• Chekmarev DS, Kholodovych V, Balakin KV, et al. Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol 2008;21:1304-14
   PubMed Web of Science ®Google Scholar
• Thai KM, Ecker GF. Classification models for HERG inhibitors by counter-propagation neural networks. Chem Biol Drug Des 2008;72:279-89
   PubMed Web of Science ®Google Scholar
• Nisius B, Goller AH, Bajorath J. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds. Chem Biol Drug Des 2009;73:17-25
   PubMed Web of Science ®Google Scholar